Company Filing History:
2 out of 48 
1 out of 1 
1 out of 119 
Years Active: 2013-2016
Title: Susanne Sebens: Innovator in Tumor Treatment
Introduction
Susanne Sebens is a prominent inventor based in Kiel, Germany. She has made significant contributions to the field of tumor treatment through her innovative research and development of specific anti-L1 antibodies. With a total of 2 patents, her work has the potential to impact cancer therapies significantly.
Latest Patents
Sebens' latest patents focus on the treatment of tumors using specific anti-L1 antibodies. The first patent describes the anti-L1 monoclonal antibody 9.3, along with related antibodies or binding molecules, and their applications in tumor treatment. This groundbreaking invention aims to provide new avenues for combating cancer effectively.
Career Highlights
Throughout her career, Susanne Sebens has worked with notable organizations, including Medigene AG and the Deutsches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts. Her experience in these institutions has allowed her to advance her research and contribute to the scientific community.
Collaborations
Sebens has collaborated with esteemed colleagues such as Daniela Kelm and Peter Altevogt. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions in cancer treatment.
Conclusion
Susanne Sebens is a dedicated inventor whose work in tumor treatment showcases her commitment to advancing medical science. Her contributions through patents and collaborations highlight her role as a key figure in the fight against cancer.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.